FDA approves HemoCleanse lung cancer study
This article was originally published in Clinica
Executive Summary
HemoCleanse and IDT have received approval from the FDA to begin a feasibility study of HemoCleanse's BioLogic-HT system for whole-body hyperthermia treatment for metastatic non-small cell lung cancer. The treatment involves elevating body temperature to control or destroy viruses and other heat sensitive organisms and HemoCleanse believes it may increase the effectiveness of chemotherapy. The study will be conducted at the University of Texas Medical Branch at Galveston, Texas.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.